- Colorectal cancer
- Linoleic acid
Objective: High-mobility group box 1 (HMGB1) was closely associated with progression and metastasis of colorectal cancer. Methods: We examined the significance of HMGB1 in causing colon carcinogenesis induced by azoxymethane (AOM) injection in Fischer 344 rats fed on a control diet (group C), a 15% linoleic acid (LA) diet (group L), a control diet with 10% glucose drink (group G), and a 15% LA diet with a 10% glucose drink (group L+G). Results: Group L+G showed the highest body weight and calorie intake. Serum and mucosal HMGB1 levels were temporally increased in all groups, while the highest levels were observed in group L+G. Mucosal HMGB1 levels were correlated with cancer multiplicity and nodal metastases. In the AOM-injected rats fed the 15% LA diet with 10% glucose drink, administration of HMGB1 antibody suppressed serum HMGB1 concentration and cancer multiplicity . Conclusion: These data suggest that dietary LA and glucose provided the synergistic effect on AOM-induced rat colon cancer through HMGB1 induction.
Copyright © 2010 S. Karger AG, Basel
- Kato H (ed): Cancer Statistics in Japan (2008). Tokyo, National Cancer Center, 2008.
- Inoue M, Iwasaki M, Otani T, Sasazuki S, Tsugane S: Public awareness of risk factors for cancer among the Japanese general population: a population-based survey. BMC Public Health 2006;6:2.
- Zhang W, Thornton WH, MacDonald RS: Insulin-like growth factor-I and II receptor expression in rat colon mucosa are affected by dietary lipid intake. J Nutr 1998;128:158–165.
- Singh J, Hamid R, Reddy BS: Dietary fish oil inhibits the expression of farnesyl protein transferase and colon tumor development in rodents. Carcinogenesis 1998;19:985–989.
- Singh J, Hamid R, Reddy BS: Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. Cancer Res 1997;57:3465–3470.
- Rao CV, Simi B, Wynn TT, Garr K, Reddy BS: Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats. Cancer Res 1996;56:532–537.
- Zhou S, Wang G, Chen B, Wang P: Effect of dietary fatty acids on tumorigenesis of colon cancer induced by methyl nitrosourea in rats. J Environ Pathol Toxicol Oncol 2000;19:81–86.
- Rao CV, Hirose Y, Indranie C, Reddy BS: Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids. Cancer Res 2001;61:1927–1933.
- Reddy BS, Sugie S: Effect of different levels of omega-3 and omega-6 fatty acids on azoxymethane-induced colon carcinogenesis in F344 rats. Cancer Res 1988;48:6642–6647.
- Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M, Hayes RP: Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev 2009;25:705–716.
- Czura CJ, Wang H, Tracey KJ: Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 2001;7:315–321.
- Degryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F, Arrigoni G, Bianchi ME: The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001;152:1197–1206.
- Fang WH, Yao YM, Shi ZG, Yu Y, Wu Y, Lu LR, Sheng ZY: The significance of changes in high mobility group-1 protein mRNA expression in rats after thermal injury. Shock 2002;17:329–333.
- Yang H, Wang H, Tracey KJ: HMG-1 rediscovered as a cytokine. Shock 2001;15:247–253.
- Schmidt AM, Yan SD, Wautier JL, Stern D: Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489–497.
- Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H: Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 2002;62:4805–4811.
- Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354–360.
- Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H, Yasui W: Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002;196:163–170.
- Kuniyasu H, Chihara Y, Takahashi T: Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 2003;10:445–448.
- Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H: Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000;275:40096–40105.
- Kuniyasu H, Chihara Y, Kondo H, Ohmori H, Ukai R: Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep 2003;10:1863–1868.
- Kuniyasu H, Chihara Y, Kondo H: Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 2003;104:722–727.
- Bhawal UK, Ozaki Y, Nishimura M, Sugiyama M, Sasahira T, Nomura Y, Sato F, Fujimoto K, Sasaki N, Ikeda MA, Tsuji K, Kuniyasu H, Kato Y: Association of expression of receptor for advanced glycation end products and invasive activity of oral squamous cell carcinoma. Oncology 2005;69:246–255.
- Sasahira T, Kirita T, Bhawal UK, Ikeda M, Nagasawa A, Yamamoto K, Kuniyasu H: The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch 2007;450:287–295.
- Kuniyasu H, Yano S, Sasaki T, Sasahira T, Sone S, Ohmori H: Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol 2005;166:751–760.
- Kuniyasu H, Sasaki T, Sasahira T, Ohmori H, Takahashi T: Depletion of tumor-infiltrating macrophages is associated with amphoterin expression in colon cancer. Pathobiology 2004;71:129–136.
- Kusume A, Sasahira T, Luo Y, Isobe M, Nakagawa N, Tatsumoto N, Fujii K, Ohmori H, Kuniyasu H: Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology 2009;76:155–162.
- Kuniyasu H, Ellis LM, Evans DB, Abbruzzese JL, Fenoglio CJ, Bucana CD, Cleary KR, Tahara E, Fidler IJ: Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res 1999;5:25–33.
- Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, Pettaway CA: Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 2000;6:2295–2308.
- Kuniyasu H, Ukai R, Johnston D, Troncoso P, Fidler IJ, Pettaway CA: The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy. Clin Cancer Res 2003;9:2185–2194.
- Schmidt AM, Hofmann M, Taguchi A, Yan SD, Stern DM: RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin Thromb Hemost 2000;26:485–493.
- Huttunen HJ, Fages C, Rauvala H: Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-ĸB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999;274:19919–19924.
- Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, Rubartelli A: The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002;3:995–1001.
- Fujii K, Luo Y, Sasahira T, Denda A, Ohmori H, Kuniyasu H: Co-treatment with deoxycholic acid and azoxymethane accelerates the secretion of HMGB1 in IEC6 intestinal epithelial cells. Cell Prolif 2009;42:701–709.
- Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191–195.
- Kuniyasu H (ed): Linoleic Acid, ed 2. Berlin, Springer, 2008.
- Kuniyasu H: The roles of dietary PPARγ ligands for metastasis in colorectal cancer. PPAR Res 2008;2008:529720.
- Yuri M, Sasahira T, Nakai K, Ishimaru S, Ohmori H, Kuniyasu H: Reversal of expression of 15-lipoxygenase-1 to cyclooxygenase-2 is associated with development of colonic cancer. Histopathology 2007;51:520–527.
- Takahashi M, Wakabayashi K: Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci 2004;95:475–480.
Dr. Hiroki Kuniyasu
Department of Molecular Pathology, Nara Medical University
Kashihara, Nara 634-8521 (Japan)
Tel. +81 74 422 3051, Fax +81 74 425 7308, E-Mail firstname.lastname@example.org
Received: January 25, 2010
Accepted after revision: March 9, 2010
Published online: July 07, 2010
Number of Print Pages : 8
Number of Figures : 3, Number of Tables : 2, Number of References : 39
Pathobiology (Exploring the basis of disease)
Vol. 77, No. 4, Year 2010 (Cover Date: July 2010)
Journal Editor: Borisch B. (Geneva), Yasui W. (Hiroshima)
ISSN: 1015-2008 (Print), eISSN: 1423-0291 (Online)
For additional information: http://www.karger.com/PAT
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.